secwatch.observer — SEC 8-K summary
======================================

Issuer:     Instil Bio, Inc. (TIL)
CIK:        0001789769
Form:       8-K
Filed at:   2022-11-08T23:59:59+00:00
Accession:  0001789769-22-000090
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Instil Bio presents CoStAR platform data at SITC; ITIL-306 Phase 1 ongoing
--------------------------------------------------------------------------

- Pre-clinical data showed CoStAR amplified T-cell responses across all FRα expression levels, supporting clinical exploration in multiple solid tumors.
- First patient dosed in ITIL-306 Phase 1 study in October 2022; evaluating safety and feasibility in advanced solid tumors.
- Treatment regimen is free of high-dose interleukin-2.
- Posters presented at SITC 2022; available on company website.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1789769/000178976922000090/0001789769-22-000090-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1789769/000178976922000090/til-20221108.htm
  HTML page:      https://secwatch.observer/filing/0001789769-22-000090

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer